Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283


Donor graft genotypes versus leukemia.

Choe HK, van Besien K.

Leuk Lymphoma. 2019 Jul;60(7):1606-1607. doi: 10.1080/10428194.2019.1613542. No abstract available.


Tocilizumab, in search for a role in acute GVHD.

Gergis U, van Besien K.

Leuk Lymphoma. 2019 Jun 25:1-3. doi: 10.1080/10428194.2019.1613545. [Epub ahead of print]


Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.

van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO.

Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.


High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.

Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB.

Bone Marrow Transplant. 2019 Jun 12. doi: 10.1038/s41409-019-0587-0. [Epub ahead of print]


It's not all about the CNS. High dose methotrexate in DLBCL.

Allan JN, Van Besien K.

Leuk Lymphoma. 2019 Aug;60(8):1845-1847. doi: 10.1080/10428194.2019.1613544. Epub 2019 May 23. No abstract available.


Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18. No abstract available.


Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.

Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.

Leuk Lymphoma. 2019 Jul;60(7):1693-1696. doi: 10.1080/10428194.2018.1543877. Epub 2019 Feb 10.


The application of precision medicine in diagnosing familial Mediterranean fever.

Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H.

Leuk Lymphoma. 2019 Aug;60(8):2091-2093. doi: 10.1080/10428194.2019.1571204. Epub 2019 Jan 30. No abstract available.


Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.

Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P, van Besien K, Mayer S.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e60-e64. doi: 10.1016/j.bbmt.2018.10.018. Epub 2018 Oct 26.


Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.

Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H.

Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019.


Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.

Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, Albano MS, Dobrila L, Scaradavou A, van Besien K.

Biol Blood Marrow Transplant. 2019 Mar;25(3):466-473. doi: 10.1016/j.bbmt.2018.11.002. Epub 2018 Nov 9.


Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.

Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ.

Bone Marrow Transplant. 2019 Jul;54(7):1058-1066. doi: 10.1038/s41409-018-0386-z. Epub 2018 Nov 1.


Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 Sep;103(9):1577. doi: 10.3324/haematol.2018.199414. No abstract available.


A renaissance for autologous transplantation in follicular lymphoma?

Chaekal OK, van Besien K.

Leuk Lymphoma. 2019 Jan;60(1):3-5. doi: 10.1080/10428194.2018.1480777. Epub 2018 Jul 3. No abstract available.


Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.

Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van Besien K.

Leuk Lymphoma. 2018 Dec;59(12):2829-2835. doi: 10.1080/10428194.2018.1455975. Epub 2018 May 23.


Colonization With Levofloxacin-resistant Extended-spectrum ╬▓-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG Jr, Jenkins SG, Walsh TJ, Kreiswirth BN.

Clin Infect Dis. 2018 Nov 13;67(11):1720-1728. doi: 10.1093/cid/ciy363.


Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 May;103(5):770-777. doi: 10.3324/haematol.2017.187047. Epub 2018 Feb 1. Erratum in: Haematologica. 2018 Sep;103(9):1577.


Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes.

Sfeir MM, Schuetz A, Van Besien K, Borczuk AC, Soave R, Jenkins SG, Walsh TJ, Small CB.

J Clin Pathol. 2018 Jul;71(7):626-630. doi: 10.1136/jclinpath-2017-204777. Epub 2018 Jan 24. Review.


Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.

Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M.

Bone Marrow Transplant. 2018 Apr;53(4):449-456. doi: 10.1038/s41409-017-0019-y. Epub 2018 Jan 12. No abstract available.


Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.

Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.

Biol Blood Marrow Transplant. 2018 May;24(5):997-1004. doi: 10.1016/j.bbmt.2017.12.794. Epub 2017 Dec 27.


Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience.

Reich-Slotky R, Cushing MM, Hsu YS, Ancharski M, Rojas JM, Scrimenti LM, Robilio S, Assalone D, Roselli T, Guarneri D, Vasovic LV, Goel R, Shore T, van Besien K.

Transfusion. 2018 Feb;58(2):339-344. doi: 10.1111/trf.14409. Epub 2017 Nov 29.


Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.

Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K.

Biol Blood Marrow Transplant. 2018 Feb;24(2):359-365. doi: 10.1016/j.bbmt.2017.10.040. Epub 2017 Nov 8.


Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.

Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K.

Biol Blood Marrow Transplant. 2018 Feb;24(2):288-293. doi: 10.1016/j.bbmt.2017.10.026. Epub 2017 Oct 20.


Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors.

Liu C, Frank DN, Horch M, Chau S, Ir D, Horch EA, Tretina K, van Besien K, Lozupone CA, Nguyen VH.

Bone Marrow Transplant. 2017 Dec;52(12):1643-1650. doi: 10.1038/bmt.2017.200. Epub 2017 Oct 2.


Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332. Lancet Haematol. 2018 Dec;5(12):e608.


Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant.

Choe HK, van Besien K.

Leuk Lymphoma. 2018 Feb;59(2):272-273. doi: 10.1080/10428194.2017.1361034. Epub 2017 Aug 16. No abstract available.


Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant.

Kanaan SB, Gammill HS, Harrington WE, De Rosa SC, Stevenson PA, Forsyth AM, Allen J, Cousin E, van Besien K, Delaney CS, Nelson JL.

Oncoimmunology. 2017 Mar 31;6(5):e1311436. doi: 10.1080/2162402X.2017.1311436. eCollection 2017.


Against the odds: haplo-cord grafts protect from GvHD and relapse.

Choe HK, van Besien K.

Bone Marrow Transplant. 2017 Dec;52(12):1590-1591. doi: 10.1038/bmt.2017.102. Epub 2017 Jun 19. No abstract available.


The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.

Leuk Lymphoma. 2018 Jan;59(1):256-258. doi: 10.1080/10428194.2017.1323270. Epub 2017 Jun 2. No abstract available.


A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R.

Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8.


The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.


Second allogeneic transplantation: ever? never? or sometimes.

Mayer S, van Besien K.

Leuk Lymphoma. 2017 Jun;58(6):1279-1280. doi: 10.1080/10428194.2016.1253839. Epub 2016 Nov 14. No abstract available.


Haploidentical cord transplantation-The best of both worlds.

van Besien K, Childs R.

Semin Hematol. 2016 Oct;53(4):257-266. doi: 10.1053/j.seminhematol.2016.07.004. Epub 2016 Jul 25. Review.


Haplo-cord transplant: HLA-matching determines graft dominance.

van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T.

Leuk Lymphoma. 2017 Jun;58(6):1512-1514. doi: 10.1080/10428194.2016.1248964. Epub 2016 Oct 27. No abstract available.


The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.

Choe HK, Gergis U, Mayer SA, Nagar H, Phillips AA, Shore TB, Smith MJ, van Besien K.

Transplantation. 2017 Jan;101(1):e34-e38. doi: 10.1097/TP.0000000000001538.


Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.

Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2100-2103. doi: 10.1016/j.bbmt.2016.08.002. Epub 2016 Aug 4.


HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders.

Dierickx D, Sprangers B, Van Besien K.

Leuk Lymphoma. 2016 Oct;57(10):2241-2. doi: 10.1080/10428194.2016.1198960. Epub 2016 Jul 5. No abstract available.


Cord blood chimerism and relapse after haplo-cord transplantation.

van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T.

Leuk Lymphoma. 2017 Feb;58(2):288-297. Epub 2016 Jun 23.


Clofarabine as a bridge to hematopoietic stem cell transplant.

Thomas CM, Ippoliti C, Roboz GJ, Feldman E, Savva D, James S, van Besien K.

Leuk Lymphoma. 2017 Jan;58(1):230-232. Epub 2016 May 31. No abstract available.


Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.

Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang HL, Maiers M, Spellman S, van Besien K, Lee SJ, Karrison T, Artz A.

Bone Marrow Transplant. 2016 Oct;51(10):1342-1349. doi: 10.1038/bmt.2016.142. Epub 2016 May 23.


Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers.

Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, Perales MA, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M.

Clin Infect Dis. 2016 Aug 15;63(4):565-8. doi: 10.1093/cid/ciw330. Epub 2016 May 19.


Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. No abstract available.


Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.

Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303. doi: 10.1016/j.clml.2016.02.004. Epub 2016 Feb 18.


Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.

Cirrone F, Ippoliti C, Wang H, Zhou XK, Gergis U, Mayer S, Shore T, van Besien K.

Leuk Lymphoma. 2016 Nov;57(11):2555-9. doi: 10.3109/10428194.2016.1157873. Epub 2016 Mar 17.


Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1065-1072. doi: 10.1016/j.bbmt.2016.02.010. Epub 2016 Feb 19.


DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center.

Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R.

Biol Blood Marrow Transplant. 2016 May;22(5):965-70. doi: 10.1016/j.bbmt.2016.02.011. Epub 2016 Feb 22.


Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A.

Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.


Engraftment for CD34 selected stem cell products is not compromised by cryopreservation.

Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM.

Transfusion. 2016 Apr;56(4):893-8. doi: 10.1111/trf.13435. Epub 2015 Dec 12.


Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.

Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K.

Biol Blood Marrow Transplant. 2016 Mar;22(3):456-61. doi: 10.1016/j.bbmt.2015.10.022. Epub 2015 Oct 31.


Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.

van Besien K.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2035-2036. doi: 10.1016/j.bbmt.2015.10.007. Epub 2015 Oct 14. No abstract available.

Supplemental Content

Loading ...
Support Center